[go: up one dir, main page]

PE20030665A1 - ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a - Google Patents

ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a

Info

Publication number
PE20030665A1
PE20030665A1 PE2002001143A PE2002001143A PE20030665A1 PE 20030665 A1 PE20030665 A1 PE 20030665A1 PE 2002001143 A PE2002001143 A PE 2002001143A PE 2002001143 A PE2002001143 A PE 2002001143A PE 20030665 A1 PE20030665 A1 PE 20030665A1
Authority
PE
Peru
Prior art keywords
aryl
inhibitors
adenosine
azepanil
piperidinyl
Prior art date
Application number
PE2002001143A
Other languages
English (en)
Inventor
Craig D Boyle
Samuel Chackalamannil
Yan Xia
Unmesh G Shah
William J Greenlee
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20030665A1 publication Critical patent/PE20030665A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A COMPUESTO CONDENSADO TRIAZO PIRIMIDIN PIRAZOL DE FORMULA I DONDE R ES R1-FURANILO, R1-TIENILO, R1-PIRIDILO, R1-OXAZOLILO, R1-PIRROLILO, R2-ARILO; X ES (CH2)n, Y ES PIPERIDINILO, PIRROLIDINILO, AZEPANILO, CON UNA PORCION ARILO O HETEROARILO FUSIONADA A DOS ATOMOS DE CARBONO ADYACENTE EN Y, X ESTA UNIDO AL ATOMO DE N DEL PIPERIDINILO, PIRROLIDINILO, AZEPANILO; Q ES H, CICLOALQUILO, CICLOHETEROALQUILO, AMINO, ARILO, ARALQUILO, HETEROARILO, ENTRE OTROS; n ES 1-4; R1 ES H, ALQUILO, CF3, HALOGENO, NO2; R2 ES H, ALQUILO, CF3, HALOGENO, NO2, ALCOXI, ACILOXI, ALQUILAMINO, ACILAMINO, ALQUILSULFONLO, HIDROXILO. TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE ADEMAS AGONISTAS DOPAMINERGICOS, INHIBIDORES DE MAO-B, INHIBIDORES DE DOPA DESCARBOXILASA, INHIBIDORES DE COMT. LOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE ENFERMEDAD DEL SISTEMA NERVIOSO CENTRAL, APOPLEJIA, ENFERMEDAD COGNITIVA, NEURODEGENERATIVA, PARKINSON, DEMENCIA SENIL
PE2002001143A 2001-11-30 2002-11-27 ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a PE20030665A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33434201P 2001-11-30 2001-11-30

Publications (1)

Publication Number Publication Date
PE20030665A1 true PE20030665A1 (es) 2003-08-08

Family

ID=23306779

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002001143A PE20030665A1 (es) 2001-11-30 2002-11-27 ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a

Country Status (18)

Country Link
US (1) US6916811B2 (es)
EP (1) EP1448565B1 (es)
JP (2) JP4284182B2 (es)
KR (1) KR20050044593A (es)
CN (1) CN1692116A (es)
AR (1) AR037680A1 (es)
AT (1) ATE453647T1 (es)
AU (1) AU2002346503A1 (es)
CA (1) CA2468649C (es)
DE (1) DE60234951D1 (es)
ES (1) ES2336435T3 (es)
HU (1) HUP0402018A3 (es)
IL (1) IL161716A0 (es)
MX (1) MXPA04005209A (es)
PE (1) PE20030665A1 (es)
TW (1) TW200306837A (es)
WO (1) WO2003048165A1 (es)
ZA (1) ZA200404161B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1283839T3 (da) * 2000-05-26 2005-07-25 Schering Corp Adenosin A2a-receptorantagonister
US6964288B2 (en) * 2001-07-06 2005-11-15 Ksaria Corporation Apparatus and method for automated preparation of an optical fiber
AR037243A1 (es) 2001-10-15 2004-11-03 Schering Corp Antagonistas del receptor de adenosina a2a,a5-amino-imidazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]pirimidina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
IL160133A0 (en) * 2002-05-30 2004-06-20 King Pharmaceuticals Res & Dev Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
EP2295047A3 (en) 2002-12-19 2011-05-18 Schering Corporation Use of adenosine A2a receptor antagonists for the treatment of restless leg syndrome and other movement disorders
JP4800216B2 (ja) * 2003-10-24 2011-10-26 エグゼリクシス, インコーポレイテッド p70S6キナーゼモジュレーターおよび使用方法
ES2278353T3 (es) * 2003-10-28 2007-08-01 Schering Corporation Procedimiento para preparar 5-amino-pirazolo-(4,3-e)-1,2,4-triazolo(1,5-c)pirimidinas sustituidas.
EP1701699B1 (en) * 2003-12-19 2011-07-13 Schering Corporation Pharmaceutical compositions of an A2a receptor antagonist
EP2258372B8 (en) * 2005-06-07 2012-12-19 Kyowa Hakko Kirin Co., Ltd. A2A antagonists for use in the treatment of motor disorders
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
US7691869B2 (en) 2007-03-30 2010-04-06 King Pharmaceuticals Research And Development, Inc. Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
PE20091102A1 (es) 2007-12-17 2009-07-25 Janssen Pharmaceutica Nv Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1
WO2010014552A1 (en) 2008-08-01 2010-02-04 Alpha Synergy Development, Inc. Vasoconstriction compositions and methods of use
US12246013B2 (en) 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
US20100203165A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
WO2010078430A1 (en) 2008-12-30 2010-07-08 Arqule, Inc. Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds
TW201100427A (en) 2009-03-31 2011-01-01 Arqule Inc Substituted heterocyclic compounds
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
CA2782872A1 (en) * 2009-12-17 2011-06-23 Alpha Synergy Development, Inc. Compositions and methods for ophthalmic delivery of nasal decongestants
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
US8999938B2 (en) 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
CN110742893B (zh) * 2018-07-23 2024-04-05 百济神州(北京)生物科技有限公司 A2a受体拮抗剂治疗癌症的方法
WO2020106560A1 (en) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
BR112021010273A2 (pt) 2018-11-30 2021-08-17 Merck Sharp & Dohme Corp. derivados de amino triazolo quinazolina substituídos em 7, 8 e 10 como antagonistas do receptor de adenosina, composições farmacêuticas e seu uso
JOP20210117A1 (ar) 2018-11-30 2023-01-30 Merck Sharp & Dohme مشتقات أمينو ترايازولو كوينازولين بها استبدال في الموضع-9 كمضادات مستقبل أدينوزين، تركيبات صيدلانية واستخدامها
DE102019116986A1 (de) 2019-06-24 2020-12-24 Helmholtz-Zentrum Dresden-Rossendorf E. V. Deuterierte 7-(3-(4-(2-([18F]Fluor)ethoxy)phenyl)propyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amin-Derivate
US20230024108A1 (en) * 2019-07-17 2023-01-26 Teon Therapeutics, Inc. Adenosine a2a receptor antagonists
CN112028891B (zh) 2019-07-30 2022-07-05 厦门宝太生物科技股份有限公司 腺苷受体拮抗剂
CN112625050B (zh) 2019-07-30 2021-10-01 杭州阿诺生物医药科技有限公司 一种a2a和/或a2b受体抑制剂的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
DE69428977T2 (de) * 1993-07-27 2002-07-11 Kyowa Hakko Kogyo Co., Ltd. Arzneimittel gegen Parkinsonsche Krankheit
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
US6448253B1 (en) * 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
US6921825B2 (en) * 1998-09-16 2005-07-26 King Pharmaceuticuals Research & Development, Inc. Adenosine A3 receptor modulators
DK1283839T3 (da) * 2000-05-26 2005-07-25 Schering Corp Adenosin A2a-receptorantagonister
IL160133A0 (en) * 2002-05-30 2004-06-20 King Pharmaceuticals Res & Dev Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
AU2004233334B2 (en) * 2003-04-23 2010-08-12 Merck Sharp & Dohme Corp. 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Also Published As

Publication number Publication date
TW200306837A (en) 2003-12-01
AR037680A1 (es) 2004-12-01
HK1063780A1 (en) 2005-01-14
IL161716A0 (en) 2004-09-27
ATE453647T1 (de) 2010-01-15
JP2008260776A (ja) 2008-10-30
WO2003048165A1 (en) 2003-06-12
US20030212059A1 (en) 2003-11-13
MXPA04005209A (es) 2004-08-19
HUP0402018A3 (en) 2008-06-30
CA2468649C (en) 2009-03-10
JP2005511699A (ja) 2005-04-28
EP1448565B1 (en) 2009-12-30
HUP0402018A2 (hu) 2005-02-28
CN1692116A (zh) 2005-11-02
DE60234951D1 (de) 2010-02-11
JP4284182B2 (ja) 2009-06-24
CA2468649A1 (en) 2003-06-12
ES2336435T3 (es) 2010-04-13
AU2002346503A1 (en) 2003-06-17
US6916811B2 (en) 2005-07-12
ZA200404161B (en) 2005-11-30
KR20050044593A (ko) 2005-05-12
EP1448565A1 (en) 2004-08-25

Similar Documents

Publication Publication Date Title
PE20030665A1 (es) ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a
PE20030477A1 (es) ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a
PE20060873A1 (es) Compuestos de quinolina heteroaromaticos
CY1114022T1 (el) Φαρμακα με δραση υποδοχεα ημ74α
ECSP034744A (es) Antagonistas de nmda/nr2b no arilo-heterociclico n-sustituidos
PE20040155A1 (es) Derivados aminoinazoles, procedimiento de preparacion e intermedios de este procedimiento a titulo de medicamentos y composiciones farmaceuticas que los contienen
BRPI0518459A2 (pt) composto ou um sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar o composto ou um sal farmaceuticamente aceitÁvel do mesmo
PE20120224A1 (es) Derivados de 1h-imidazo-[4,5-c]-quinolinona
ECSP056072A (es) Pirimidinonas sustituidas
PE20061378A1 (es) INHIBIDORES DE LA ACTIVIDAD DE Akt
PE20040450A1 (es) Heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida como inhibidores de metaloproteinasa
PE20060334A1 (es) Derivados de piridina como antagonistas del receptor a2b de adenosina
SG166019A1 (en) Quinoline derivatives and use thereof as mycobacterial inhibitors
GT200400092A (es) Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad
PE20060775A1 (es) Derivados de pirrolidilo de compuestos heteroaromaticos como inhibidores de fosfodiesterasa
PE20070832A1 (es) Derivados de piridazinona como inhibidores de la tirosina quinasa
BRPI0412894A (pt) tienopiridina e furopiridina inibidores de quinases
PE20080059A1 (es) Quinazolinas para la inhibicion de pdk1
DE60235396D1 (de) 3-amido-1,2-benzisoxazolderivate, herstellungsverfahren und deren verwendung
PE20091376A1 (es) Derivados de fenilamino como moduladores de beta-amiloide
UY28150A1 (es) Agentes terapeuticos
DE60318583D1 (de) N-äphenyl(piperidin-2-yl)methylübenzamid-derivate, verfahren zu deren herstellung und ihre therapeutische verwendung
DE60211343D1 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
PE20070069A1 (es) Piperazin-piperidinas como antagonistas y agonistas del receptor 5-ht1a
AR052312A1 (es) 2- anilinopirimidinas sustituidas como inhibidores de la quinasa del ciclo celular o del receptor de la tirosina quinasa, su preparacion y medicamentos preparados en base al compuesto

Legal Events

Date Code Title Description
FC Refusal